NCT04294771 (JOCARDITE) is a clinical trial of ICI in Myocarditis, sponsored by Groupe Hospitalier Pitie-Salpetriere.

Who is sponsoring NCT04294771?

NCT04294771 is sponsored by Groupe Hospitalier Pitie-Salpetriere.

What drugs are being tested in NCT04294771?

Interventions in NCT04294771: ICI.

What condition does NCT04294771 study?

NCT04294771 studies Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Pericarditis, Vasculitis.

Is NCT04294771 still recruiting?

NCT04294771 is currently status unknown. Last updated 15 September 2023.

Last reviewed 2023-09-15 · How we verify

NCT04294771: JOCARDITE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

Status unknown Last updated 15 September 2023

What this trial tests

trial testing ICI in Myocarditis in 500,000 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 January 2025

1 January 2025

Quick facts

Lead sponsor	Groupe Hospitalier Pitie-Salpetriere
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500,000
Start date	1 January 2019
Primary completion	1 January 2025
Estimated completion	1 January 2025
Sites	1 location across France

Drugs / interventions tested

ICI — full drug profile →

Conditions studied

Myocarditis — all drugs for Myocarditis →
Cardiomyopathies — all drugs for Cardiomyopathies →
Heart Diseases — all drugs for Heart Diseases →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Groupe Hospitalier Pitie-Salpetriere

Who can join

Eligibility, any sex, with Myocarditis or Cardiomyopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system. This study investigates reports of cardio-vascular toxicity associated with treatment including anti-PD1, Anti-PDL-1, and Anti CTLA4 classes using the World Health Organization (WHO) database VigiBase, Assistance Publique Hopitaux de Paris Entrepot de Données de Santé (APHP.EDS), French Système National Des Données de Santé (SNDS) Databases and a retrospective international multicenter registry of ICI-associated myocarditis

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann LH, Heckmann MB, Bailly G, Finke D, et al · · 2023 · cited 106× · PMID 37317858 · DOI 10.1161/circulationaha.123.062405
Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis.
Power JR, Alexandre J, Choudhary A, Ozbay B, et al · · 2021 · cited 94× · PMID 34723640 · DOI 10.1161/circulationaha.121.055816
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: <i>JACC: CardioOncology</i> State-of-the-Art Review.
Suero-Abreu GA, Zanni MV, Neilan TG. · · 2022 · cited 67× · PMID 36636438 · DOI 10.1016/j.jaccao.2022.11.011
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
Nguyen LS, Bretagne M, Arrondeau J, Zahr N, et al · · 2022 · cited 67× · PMID 35383117 · DOI 10.1136/jitc-2022-004699
Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
Wilcox NS, Rotz SJ, Mullen M, Song EJ, et al · · 2022 · cited 60× · PMID 35175846 · DOI 10.1161/circresaha.121.319901
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
Zhang Y, Sun C, Li Y, Qin J, et al · · 2022 · cited 50× · PMID 36322628 · DOI 10.1126/scitranslmed.abo1981
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.
Moslehi J, Salem JE. · · 2022 · cited 36× · PMID 36636442 · DOI 10.1016/j.jaccao.2022.11.005
Immune checkpoint inhibitor-associated myocarditis: a novel risk score.
Power JR, Dolladille C, Ozbay B, Procureur A, et al · · 2026 · cited 25× · PMID 40569849 · DOI 10.1093/eurheartj/ehaf315

Verify or expand the search:

Other trials of ICI

Trials testing the same drug.

NCT06524570 — Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy · Phase 1 · recruiting
NCT05378334 — Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients · NA · recruiting
NCT04680598 — Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent An · unknown
NCT03387540 — Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions · completed

Other recruiting trials for Myocarditis

Currently open trials in the same condition.

NCT06889662 — GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis. · recruiting
NCT06730607 — Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-contr · recruiting
NCT06566209 — FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis · recruiting
NCT07086144 — Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis · NA · recruiting
NCT06158698 — CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine · Phase 3 · recruiting

Other Groupe Hospitalier Pitie-Salpetriere trials

Trials by the same sponsor.

NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04294771 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
Last refreshed: 15 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04294771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing